Indoloxytriazines as binding molecules for the JAK2 JH2 pseudokinase domain and its V617F variant
- 1 August 2021
- journal article
- research article
- Published by Elsevier BV in Tetrahedron Letters
Abstract
No abstract availableKeywords
Funding Information
- Argonne National Laboratory (DE-AC02-06CH11357, P30 GM124165)
- Office of Research Infrastructure Programs, National Institutes of Health (1S10OD018007-01, S10OD021527)
- Deutsche Forschungsgemeinschaft (KR 5228/1-1)
- National Institutes of Health (GM007324, GM32136)
- Office of Science
- U.S. Department of Energy
This publication has 19 references indexed in Scilit:
- ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activationProceedings of the National Academy of Sciences of the United States of America, 2015
- Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617FNature Structural & Molecular Biology, 2012
- Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein−Ligand ComplexesJournal of Medicinal Chemistry, 2006
- Molecular modeling of organic and biomolecular systems using BOSS and MCPROJournal of Computational Chemistry, 2005
- A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancerNature Genetics, 2005
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersThe New England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking AccuracyJournal of Medicinal Chemistry, 2004